The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Health and Economic Implications of HPV Vaccination in the United States
Open accessAbstract
BACKGROUND: The cost-effectiveness of prophylactic vaccination against human papillomavirus types 16 (HPV-16) and 18 (HPV-18) is an important consideration for guidelines for immunization in the United States. METHODS: We synthesized epidemiologic and demographic data using models of HPV-16 and HPV-18 transmission and cervical carcinogenesis to compare the health and economic outcomes of vaccinating preadolescent girls (at 12 years of age) and vaccinating older girls and women in catch-up programs (to 18, 21, or 26 years of age). We examined the health benefits of averting other HPV-16-related and HPV-18-related cancers, the prevention of HPV-6-related and HPV-11-related genital warts and juvenile-onset recurrent respiratory papillomatosis by means of the quadrivalent vaccine, the duration of immunity, and future screening practices. RESULTS: On the assumption that the vaccine provided lifelong immunity, the cost-effectiveness ratio of vaccination of 12-year-old girls was $43,600 per quality-adjusted life-year (QALY) gained, as compared with the current screening practice. Under baseline assumptions, the cost-effectiveness ratio for extending a temporary catch-up program for girls to 18 years of age was $97,300 per QALY; the cost of extending vaccination of girls and women to the age of 21 years was $120,400 per QALY, and the cost for extension to the age of 26 years was $152,700 per QALY. The results were sensitive to the duration of vaccine-induced immunity; if immunity waned after 10 years, the cost of vaccination of preadolescent girls exceeded $140,000 per QALY, and catch-up strategies were less cost-effective than screening alone. The cost-effectiveness ratios for vaccination strategies were more favorable if the benefits of averting other health conditions were included or if screening was delayed and performed at less frequent intervals and with more sensitive tests; they were less favorable if vaccinated girls were preferentially screened more frequently in adulthood. CONCLUSIONS: The cost-effectiveness of HPV vaccination will depend on the duration of vaccine immunity and will be optimized by achieving high coverage in preadolescent girls, targeting initial catch-up efforts to women up to 18 or 21 years of age, and revising screening policies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Quadrivalent Vaccine against Human Papillomavirus to Prevent High-Grade Cervical Lesions
(2007) · New England Journal of Medicine · doi:10.1056/nejmoa061741 · Cited by 2,055
Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases
Garland, S. M., Hernandez-Avila, M., Wheeler, C. M., Perez, G., Harper, D. M., Leodolter, S., Tang, G. W. K., Ferris, D. G., Steben, M., Bryan, J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa061760 · Cited by 1,886
Markowitz, L. E., Dunne, E. F., Saraiya, M., Lawson, H. W., Chesson, H., & Unger, E. R. (2007) · PsycEXTRA Dataset · doi:10.1037/e601292007-001 · Cited by 1,882
Harper, D. M., Franco, E. L., Wheeler, C. M., Moscicki, A.-B., Romanowski, B., Roteli-Martins, C. M., Jenkins, D., Schuind, A., Costa Clemens, S. A., & Dubin, G. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68439-0 · Cited by 1,632
Le, M. (2007) · Medical Entomology and Zoology · Cited by 1,624
Prevalence of HPV Infection Among Females in the United States
Dunne, E. F., Unger, E. R., Sternberg, M., McQuillan, G., Swan, D. C., Patel, S. S., & Markowitz, L. E. (2007) · JAMA · doi:10.1001/jama.297.8.813 · Cited by 1,579
Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis
Clifford, G. M., Smith, J. S., Plummer, M., Muñoz, N., & Franceschi, S. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6600688 · Cited by 1,561
Births: preliminary data for 2012.
Hamilton, B. E., Martin, J. A., & Ventura, S. J. (2013) · PubMed · Cited by 1,509
Chapter 2: The burden of HPV-related cancers
Parkin, D. M., & Bray, F. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.05.111 · Cited by 1,385
Paavonen, J., Jenkins, D., Bosch, F. X., Naud, P., Salmerón, J., Wheeler, C. M., Chow, S.-N., Apter, D. L., Kitchener, H. C., Castellsague, X., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60946-5 · Cited by 1,315
2001 Consensus Guidelines for the Management of Women With Cervical Cytological Abnormalities
Wright, Jr. (2002) · JAMA · doi:10.1001/jama.287.16.2120 · Cited by 1,215
Clifford, G., Gallus, S., Herrero, R., Muñoz, N., Snijders, P., Vaccarella, S., Anh, P., Ferreccio, C., Hieu, N., Matos, E., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67069-9 · Cited by 1,093
Winer, R. L. (2003) · American Journal of Epidemiology · doi:10.1093/aje/kwf180 · Cited by 1,044
American Cancer Society Guideline for the Early Detection of Cervical Neoplasia and Cancer
Saslow, D., Runowicz, C. D., Solomon, D., Moscicki, A.-B., Smith, R. A., Eyre, H. J., & Cohen, C. (2002) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.52.6.342 · Cited by 927
2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests
Wright, T. C., Massad, L. S., Dunton, C. J., Spitzer, M., Wilkinson, E. J., & Solomon, D. (2007) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2007.07.047 · Cited by 841
Eichler, H.-G., Kong, S. X., Gerth, W. C., Mavros, P., & Jönsson, B. (2004) · Value in Health · doi:10.1111/j.1524-4733.2004.75003.x · Cited by 788
The Beaver Dam Health Outcomes study: Initial Catalog of Health-state Quality Factors
Fryback, D. G., Dasbach, E. J., Klein, R., Klein, B. E. K., Dorn, N., Peterson, K., & Martin, P. A. (1993) · Medical Decision Making · doi:10.1177/0272989x9301300202 · Cited by 733
Sexual Behavior and Selected Health Measures: Men and Women 15-44 Years of Age, United States, 2002
Mosher, W. D., Chandra, A., & Jones, J. (2005) · PsycEXTRA Dataset · doi:10.1037/e609202007-001 · Cited by 693
Clifford, G. M., Smith, J. S., Aguado, T., & Franceschi, S. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6601024 · Cited by 684
International union against cancer
Sherman, C. (1988) · Journal of Cancer Education · doi:10.1080/08858198809527918 · Cited by 641
Ault, K. A. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60852-6 · Cited by 590
Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases
Clifford, G., Franceschi, S., Diaz, M., Muñoz, N., & Villa, L. L. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.05.026 · Cited by 568
Projected Clinical Benefits and Cost-effectiveness of a Human Papillomavirus 16/18 Vaccine
Goldie, S. J., Kohli, M., Grima, D., Weinstein, M. C., Wright, T. C., Bosch, F. X., & Franco, E. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh104 · Cited by 539
Self-citationChapter 4: Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease
Lacey, C. J. N., Lowndes, C. M., & Shah, K. V. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.06.015 · Cited by 535
Saslow, D., Castle, P. E., Cox, J. T., Davey, D. D., Einstein, M. H., Ferris, D. G., Goldie, S. J., Harper, D. M., Kinney, W., Moscicki, A.-B., et al. (2007) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.57.1.7 · Cited by 521
Self-citationWright, T. C., Schiffman, M., Solomon, D., Cox, J. T., Garcia, F., Goldie, S., Hatch, K., Noller, K. L., Roach, N., Runowicz, C., et al. (2004) · Obstetrics & Gynecology · doi:10.1097/01.aog.0000109426.82624.f8 · Cited by 499
Self-citationModel for Assessing Human Papillomavirus Vaccination Strategies
Elbasha, E. H., Dasbach, E. J., & Insinga, R. P. (2007) · Emerging Infectious Diseases · doi:10.3201/eid1301.060438 · Cited by 491
Mao, C., Koutsky, L. A., Ault, K. A., Wheeler, C. M., Brown, D. R., Wiley, D. J., Alvarez, F. B., Bautista, O. M., Jansen, K. U., & Barr, E. (2006) · Obstetrics & Gynecology · doi:10.1097/01.aog.0000192397.41191.fb · Cited by 451
Evaluating Human Papillomavirus Vaccination Programs
Taira, A. V., Neukermans, C. P., & Sanders, G. D. (2004) · Emerging Infectious Diseases · doi:10.3201/eid1011.040222 · Cited by 379
Gold, M. R., Franks, P., McCoy, K. I., & Fryback, D. G. (1998) · Medical Care · doi:10.1097/00005650-199806000-00002 · Cited by 357
Potential Health and Economic Impact of Adding a Human Papillomavirus Vaccine to Screening Programs
Kulasingam, S. L. (2003) · JAMA · doi:10.1001/jama.290.6.781 · Cited by 337
Cost Effectiveness of a Potential Vaccine for Human papillomavirus
Sanders, G. D., & Taira, A. V. (2003) · Emerging Infectious Diseases · doi:10.3201/eid0901.020168 · Cited by 310
Barnabas, R. V., Laukkanen, P., Koskela, P., Kontula, O., Lehtinen, M., & Garnett, G. P. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030138 · Cited by 293
Goldhaber-Fiebert, J. D., Stout, N. K., Salomon, J. A., Kuntz, K. M., & Goldie, S. J. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn019 · Cited by 286
Self-citationChapter 12: Prophylactic HPV vaccines: Underlying mechanisms
Stanley, M., Lowy, D. R., & Frazer, I. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.05.110 · Cited by 262
Births: preliminary data for 2002.
Hamilton, B. E., Martin, J. A., & Sutton, P. D. (2003) · PubMed · Cited by 260
2001 Consensus Guidelines for the Management of Women with Cervical Cytological Abnormalities
Wright, T. C., Cox, J. T., Massad, L. S., Twiggs, L. B., & Wilkinson, E. J. (2002) · Journal of Lower Genital Tract Disease · doi:10.1097/00128360-200204000-00012 · Cited by 255
Chapter 20: Issues in planning cervical cancer screening in the era of HPV vaccination
Franco, E. L., Cuzick, J., Hildesheim, A., & de Sanjosé, S. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.05.061 · Cited by 236
The Theoretical Population-Level Impact of a Prophylactic Human Papilloma Virus Vaccine
Hughes, J. P., Garnett, G. P., & Koutsky, L. (2002) · Epidemiology · doi:10.1097/00001648-200211000-00006 · Cited by 230
Insinga, R. P., Dasbach, E. J., & Myers, E. R. (2003) · Clinical Infectious Diseases · doi:10.1086/375074 · Cited by 216
Goldie, S. J., Kim, J. J., & Wright, T. C. (2004) · Obstetrics & Gynecology · doi:10.1097/01.aog.0000120143.50098.c7 · Cited by 209
Self-citationPrevalence and determinants of human papillomavirus genital infection in men
Franceschi, S., Castellsagué, X., Dal Maso, L., Smith, J. S., Plummer, M., Ngelangel, C., Chichareon, S., Eluf-Neto, J., Shah, K. V., Snijders, P. J. F., et al. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600194 · Cited by 196
Insinga, R. P., Dasbach, E. J., & Elbasha, E. H. (2005) · PharmacoEconomics · doi:10.2165/00019053-200523110-00004 · Cited by 195
Revised guidelines for HIV counseling, testing, and referral.
(2001) · PubMed · Cited by 189
Dasbach, E. J. (2006) · Epidemiologic Reviews · doi:10.1093/epirev/mxj006 · Cited by 181
Births: preliminary data for 2005.
Hamilton, B. E., Martin, J. A., & Ventura, S. J. (2006) · PubMed · Cited by 176
The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada
Brisson, M., Van de Velde, N., De Wals, P., & Boily, M.-C. (2007) · Vaccine · doi:10.1016/j.vaccine.2007.04.086 · Cited by 175
The economic burden of noncervical human papillomavirus disease in the United States
Hu, D., & Goldie, S. J. (2008) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2008.03.064 · Cited by 170
Self-citationCost-effectiveness of HPV 16, 18 vaccination in Brazil
Goldie, S. J., Kim, J. J., Kobus, K., Goldhaber-Fiebert, J. D., Salomon, J., O'Shea, M. K. H., Xavier Bosch, F., de Sanjosé, S., & Franco, E. L. (2007) · Vaccine · doi:10.1016/j.vaccine.2007.05.058 · Cited by 167
Self-citationMultiparameter calibration of a natural history model of cervical cancer
Kim, J. J., Kuntz, K. M., Stout, N. K., Mahmud, S., Villa, L. L., Franco, E. L., & Goldie, S. J. (2007) · American Journal of Epidemiology · doi:10.1093/aje/kwm086 · Cited by 161
Self-citationKim, J. J., Andres-Beck, B., & Goldie, S. J. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6604023 · Cited by 156
Self-citationCost-effectiveness analyses of human papillomavirus vaccination
Newall, A. T., Beutels, P., Wood, J., Edmunds, W. J., & MacIntyre, C. R. (2007) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(07)70083-x · Cited by 127
National vaccination coverage among adolescents aged 13-17 years--United States, 2006.
(2007) · PubMed · Cited by 83
Eltoum, I. A., & Roberson, J. (2007) · Cancer · doi:10.1002/cncr.22487 · Cited by 59
Pap Screening in a U.S. Health Plan
Insinga, R. P., Glass, A. G., & Rush, B. B. (2004) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.355.13.3 · Cited by 57
Boot, H. J., Wallenburg, I., de Melker, H. E., Mangen, M.-J. J., Gerritsen, A. A. M., der Maas, N. A. V., Berkhof, J. H., Meijer, C. J. L. M., & Kimman, T. G. (2007) · Vaccine · doi:10.1016/j.vaccine.2007.05.061 · Cited by 50
Economic evaluations of human papillomavirus vaccines
Barnabas, R. V., & Kulasingam, S. (2007) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1586/14737167.7.3.251 · Cited by 14
Drews, J. (2007) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1586/14737167.7.1.1 · Cited by 7
Cited by
Human Papillomavirus and Rising Oropharyngeal Cancer Incidence in the United States
Chaturvedi, A. K., Engels, E. A., Pfeiffer, R. M., Hernandez, B. Y., Xiao, W., Kim, E., Jiang, B., Goodman, M. T., Sibug-Saber, M., Cozen, W., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.4596 · Cited by 3,638
Special Issue: KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients
Eckardt, K.-U., Kasiske, B. L., & Zeier, M. G. (2009) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2009.02834.x · Cited by 1,499
The global incidence of lip, oral cavity, and pharyngeal cancers by subsite in 2012
Shield, K. D., Ferlay, J., Jemal, A., Sankaranarayanan, R., Chaturvedi, A. K., Bray, F., & Soerjomataram, I. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21384 · Cited by 724
Lehtinen, M., Paavonen, J., Wheeler, C. M., Jaisamrarn, U., Garland, S. M., Castellsagué, X., Skinner, S. R., Apter, D., Naud, P., Salmerón, J., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70286-8 · Cited by 704
Surveillance of vaccination coverage among adult populations—United States, 2015.
Williams, W. W., Lu, P.-J., O’Halloran, A., Kim, D. K., Grohskopf, L. A., Pilishvili, T., Skoff, T. H., Nelson, N. P., Harpaz, R., Markowitz, L. E., et al. (2017) · MMWR Surveillance Summaries · doi:10.15585/mmwr.ss6611a1 · Cited by 442
Metadata
- Authors
- Kim, J. J., & Goldie, S. J.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-08-21
- Volume
- 359
- Issue
- 8
- Pages
- 821-832
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2160524427
- Cited by
- 365
- References
- 58
- FWCI
- 32.63
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.